Format

Send to

Choose Destination
Nat Rev Immunol. 2018 Mar;18(3):212-219. doi: 10.1038/nri.2017.89. Epub 2017 Aug 30.

Synthetic immune niches for cancer immunotherapy.

Author information

1
Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 26, 6525 GA, Nijmegen, the Netherlands.
2
Department of Biomedical Engineering, Laboratory of Immunoengineering, Eindhoven University of Technology, 5600 MB, Eindhoven, the Netherlands; and at the Institute for Complex Molecular Systems, Eindhoven University of Technology, 5600 MB, Eindhoven, the Netherlands.

Abstract

Cancer immunotherapy can successfully promote long-term anticancer immune responses, although there is still only a limited number of patients who benefit from such treatment, and it can sometimes have severe treatment-associated adverse events. Compared with systemic immunomodulation, local immunomodulation may enable more effective treatment at lower doses and, at the same time, prevent systemic toxicity. Local delivery of engineered three-dimensional scaffolds may fulfil this role by acting as synthetic immune niches that boost anticancer immunity. In this Opinion article, we highlight the potential of scaffold-based adoptive cell transfer and scaffold-based cancer vaccines that, although applied locally, can promote systemic antitumour immunity. Furthermore, we discuss how scaffold-based cancer immunotherapy may contribute to the development of the next generation of cancer treatments.

PMID:
28853444
DOI:
10.1038/nri.2017.89

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center